# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Prop...
HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target...
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of ...
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate o...